**Table S1.** Exclusion criteria

|  |
| --- |
| * Current symptoms were better explained by symptoms of major depressive disorder or bipolar disorder;
* Symptoms were fully explained by pre-existing conditions that may cause cognitive impairment or symptoms similar to those seen in PCC [e.g., attention deficit/hyperactivity disorder (ADHD), major neurocognitive disorder, schizophrenia, chronic fatigue syndrome (CFS)/encephalitis meningitis (EM), as assessed by Mini International Neuropsychiatric Interview (M.I.N.I.) 7.0.2];
* Known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated inefficacy;
* Current alcohol and/or substance use disorder, as confirmed by the M.I.N.I. 7.0.2;
* Presence of comorbid psychiatric disorder that is a primary focus of clinical concern, as confirmed by the M.I.N.I. 7.0.2;
* Previous history of mania/hypomania;
* Taking medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants);
* Any medication for a general medical disorder that may affect cognitive function (as per clinical judgment);
* Use of benzodiazepines within 12 hours of cognitive assessments;
* Consumption of alcohol within eight hours of cognitive assessments;
* Any physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments;
* Diagnosed reading disability or dyslexia;
* Clinically significant learning disorder by history;
* Treatment with electroconvulsive therapy (ECT) in the last 6 months;
* History of moderate or severe head trauma (e.g., loss of consciousness for > 1 hour), other neurological disorders, or unstable systemic medical diseases that are likely to affect the central nervous system (as per clinical judgment);
* Pregnant and/or breastfeeding; received investigational agents as part of a separate study within 30 days of the screening visit;
* Actively suicidal/presence of suicidal ideation or evaluated as being at suicide risk (as per clinical judgment);
* Currently receiving treatment with monoamine oxidase inhibitor (MAOI) antidepressants, antibiotics such as linezolid or intravenous methylene blue;
* Previous hypersensitivity reaction to vortioxetine or any components of the formulation;
* Previously reported angioedema in persons treated with vortioxetine;
* Serotonin syndrome;
* Abnormal bleeding;
* Angle closure glaucoma;
* Hyponatremia;
* Moderate hepatic impairment;
* Active seizure disorder/epilepsy that is not controlled by medication (as per clinical judgment);
* Presence of any unstable medical conditions;
* Inability to follow study procedures;
* And inability to give informed consent.
 |